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Summary
In breast cancer CA 15.3 is considered the tu-
mour marker of choice. CA 15.3 is directly re-
lated to the disease extent and to hormone 
status (estrogen receptor ER+/ ER–, proges-
terone receptor PR+/PR–). This study was de-
signed to assess the impact of disease ex-
tent, hormone receptor and HER2-status, and 
circulating blood volume on the area-under 
the ROC-curve of CA 15.3 to separate FDG 
PET positive from negative findings. Patients, 
methods: We retrospectively evaluated 379 
FDG PET/CT examinations performed in 80 
patients with breast cancer. Blood volumes 
were derived using the formulas by Nadler 
and multiplied by their corresponding CA 
15.3 measurement. Results: ROC-curve 
analysis revealed an AUC of 0.695 (p = 
0.0001) for CA 15.3 to separate FDG PET 
positive from negative findings. AUC 
measurements to separate normal scan find-
ings from loco-regional disease and meta-
static disease were 0.527 (p = 0.587) and 
0.732 (p = 0.0001), respectively. AUC 
measurements for CA 15.3 to separate posi-
tive from negative FDG PET findings, in ER+ 
and ER– patients, were respectively 0.772 (p = 
0.0001) and 0.596 (p = 0.143). AUC measure-
ments for CA 15.3 to separate positive from 
negative FDG PET findings, in PR+ and PR– 
patients, were respectively 0.675 (p = 0.0001) 
and 0.694 (p = 0.0001). In HER2-positive and 
-negative patients, the AUC measurements 
were respectively 0.594 (p = 0.178) and 0.701 
(p = 0.0001) to separate positive from 
negative FDG PET findings. Conclusion: The 
AUC for CA 15.3 measurements to separate 
FDG PET positive from negative findings in 
breast cancer patients with suspected recur-
rence proved to be directly related to the ex-
tent of the recurrent disease and hormone re-
ceptor status and inversely related to 
HER2-status. Correcting CA15.3 measure-
ments for blood volumes did not impact the 
AUC.
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In breast cancer, Cancer Antigen 15.3 (CA 
15.3) is considered the serum tumor 
marker of choice (18). CA 15–3 is an epi-
tope of a large trans-membrane glycopro-
tein named MUC1 that is derived from the 
MUC1 gene. Two possible mechanisms 
have been proposed to account for its pro-
duction. 
• The extracellular domain of MUC1 can 
be released into serum via proteolytic 
cleavage. 
• Translation products of the MUC-1 
gene have been described that lack the 
trans-membrane and cytoplasmic do-
main as well as the proteolytic cleavage 
site that may be directly secreted from 
the cell, MUC-1/SEC (17, 23).
Following curative treatment for breast 
cancer, limited data suggest that regular 
serum measurements of CA 15.3 may pro-
vide a lead-time of 2–9 months for early re-
currence detection (5, 7). Accordingly, in 
many centres worldwide, serial measure-
ments of CA 15.3 are part of the routine 
follow-up of breast cancer patients. How-
ever, CA 15.3 serum measurements lack 
specificity and do not predict the number 
and location of recurrent disease (12). 
Thus, in clinical practice, CA 15.3 serum 
measurements are being complemented by 
conventional morphological imaging or 
since recently by FDG PET/CT imaging. 
FDG PET/CT imaging which was shown 
to have an overall pooled accuracy of 83% 
for breast cancer recurrence detection 
when a CA 15.3 increase is found (8). 
While CA 15.3 levels have proven system-
atically higher in PET positive versus PET 
negative patients, to date no single cut-off 
value yielding an acceptable accuracy to 
base the prescription of an FDG PET/CT 
examination on has been identified. Using 
various cut-off levels for CA 15.3, sensitiv-
ities for FDG PET/CT imaging for breast 
cancer recurrence detection ranging from 
75–96% and specificities ranging from 
50–100% have been reported (3, 10, 16, 
20). 
Of interest, CA 15.3 levels have proven 
directly related to the disease extent (loco-
regional versus metastatic) and increases 
are more pronounced and more frequent in 
hormone receptor positive patients as op-
posed to hormone receptor negative pa-
tients (17, 22, 23). Also, for similar sized 
breast lesions producing similar amounts 
of soluble MUC-1 in different patients, dif-
ferent CA 15.3 measurements may be ob-
tained due to differences in blood volume; 
smaller blood volumes will yield higher CA 
15.3 measurements. Thus, the aims of this 
study were to assess the impact of disease 
extent (loco-regional versus metastatic), 
hormone receptor status and circulating 
blood volume on the area-under the ROC-
curve of CA 15.3 serum levels for separat-
ing FDG PET positive from FDG PET 
negative findings in breast cancer patients. 
Patients and methods
From 2005 until 2013, 379 FDG PET/CT 
examinations were performed in 80 
women suffering from breast carcinoma 
(51.4 years, 30–75.8 years) who presented 
with clinical signs suggestive of breast 
cancer recurrence, doubtful chest and bone 
radiography and equivocal whole body im-
aging bone scintigraphy. All patients had 
been previously treated according to their 
disease stage and taking into account im-
munohistochemical features (▶ Tab. 1). Of 
the 379 PET/CTs, 164 PETs were perform-
ed during hormonal therapy. In patients 
that had been treated with chemotherapy, a 
delay of 6 weeks was respected between the 
date of last treatment and imaging. For all 
imaging sessions, recent CA 15.3 measure-
ments were available (performed within 7 
days of the FDG PET/CT examination). 
Blood volumes were derived using the for-
mulas by Nadler et al. for men and women 
based on height and weight (blood volume 
of men = 0.3669Ht3 + 0.03219 Wt + 0.6041, 
blood volume in women = 0.3561Ht3 + 
0.03308Wt+ 0.1833 (Ht = height in m and 
Wt = weight in kg). Blood volumes were 
multiplied by their corresponding CA 15.3 
measurement yielding the total estimated 
amount of CA 15.3 shedded and/or se-
creted.
CA 15.3 determination
CA 15.3 blood levels were assessed using a 
commercially available radioimmunoassay. 
Using this assay, abnormal values are de-
fined as ≥ 25 IU/ml.
FDG PET-CT imaging
FDG PET-CT examinations were perform-
ed on a dedicated BGO PET system with a 
helical CT (discovery ST; GE Medical Sys-
tems, Milwaukee, WI, USA). Whole body 
images (from the base of the skull to the 
proximal third of the femora) were ac-
quired 60 minutes following the injection 
of FDG. The dose injected per patient was 
defined using the following formula (body 
weight-10) x 3 MBq with a minimum ac-
tivity of 180 MBq and a maximum activity 
of 300 MBq. Images were reconstructed 
using an ordered subset expectation maxi-
Tab. 1 Patient characteristics
characteristics (n = 80)
age (years)
number of PETs per patient
time interval PET/d
stage at 
diagnosis (%)
hormonal 
receptors, 
n (%)
HER2, n (%)
PET performed 
during
mean 
range
 I
 II
 III
 IV
 NA
ER–/PR–
ER+/PR–
 ER+/PR+
ER–/PR+
negative
positive
All
CT
HT
value
51.4
30 – 75.8
1 – 16
682.6 (0–2073)
19 (23.8)
26 (32.5)
23 (28.7)
8 (10)
4 (5)
12
14
50
4
61 (76%)
19 (24%)
379
215
164
Tab. 2  
Correlation between 
FDG-PET and CA 15.3
CA 15.3 positive
negative
total
FDG/PET
positive,
211
62
273
negative
60
46
106
total
271
108
379
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mization algorithm provided by the ven-
dor.
Image interpretation
Two experienced nuclear medicine phys-
icians visually evaluated reconstructed im-
ages and in case of discrepancy (none) a 
final diagnosis was reached by consensus. 
Any non-physiological, increased FDG up-
take with either highly suspicious or defi-
nite morphological changes was considered 
as pathological. The absence of FDG up-
take aside from normal physiological up-
take was considered as a negative FDG-
PET-CT examination. 
Follow-up
In all patients, a conclusive diagnosis was 
obtained from the results of histopath-
ological examination or from clinical/im-
aging follow-up. Biopsy was not performed 
if metastases were multiple or bone-rel-
evant. Clinical and radiological recurrences 
were defined as the detection of recurrent 
disease by abnormal clinical visit, a con-
tinuous rise in CA 15.3 levels or the ap-
pearance of new lesions or size increase of 
old lesions on imaging examinations. For 
all patients the absence or presence of dis-
ease was confirmed by long term follow up 
with control visits every 3 to 6 months for 
at least 12 months. 
Statistical analysis
SPSS_version 20.0 was used for statistical 
analysis. Continuous data were described 
as mean +/- standard deviation (normal 
distribution). Comparisons of continuous 
variables were performed using either an 
unpaired student t-test (two groups) or 
ANOVA with post-hoc Bonferroni correc-
tion (three groups). Receiver-operating-
characteristics (ROC)-curve analysis was 
performed to define the discriminatory 
value of CA 15.3 measurements as well as 
blood volume corrected CA 15.3 measure-
ments to separate FDG PET-CT positive 
(recurrence) from negative (absence of re-
currence) findings in various subgroups of 
patients. To illustrate differences we pres-
ent data in boxplots whenever relevant.
Results
Whole group
Patient data are shown (▶ Tab. 1). CA 15.3 
levels varied from 0–1140 IU/ml (mean: 
103.8 IU/ml (SD: 236 IU/ml). In 273 out of 
379 imaging sessions, FDG PET-CT im-
aging proved positive for malignancy. In 47 
sessions, locoregional disease was found. In 
226 imaging sessions, metastatic disease 
was found. In the remaining 106 imaging 
sessions, FDG PET-CT imaging proved 
negative for malignancy. Using a cut-off of 
> 25 IU/ml, increased CA 15.3 values were 
concordant with imaging results in 257 im-
aging sessions (both positive in 211 im-
aging sessions and both negative in 46 im-
aging sessions) (▶ Tab. 2). ROC-curve 
analysis revealed an AUC of 0.695 with 
95%CI: [0,642–0,740] for CA 15.3 to separ-
ate FDG PET-CT positive from FDG PET-
CT negative findings (▶ Fig. 1). 
Locoregional versus metastatic 
disease
FDG PET-CT imaging proved negative in 
106 imaging sessions, mean CA 15.3 level 
was 33.8 IU/ml (range: 8–127 IU/ml; SD: 
22.2 IU/ml). In 47 image sessions, FDG 
PET-CT imaging showed loco-regional 
disease, mean CA 15.3 level was 55.2 IU/ml 
(range: 10–403 IU/ml; SD: 76 IU/ml). In 
the remaining 226 sessions, FDG PET-CT 
imaging put to evidence metastatic disease 
(combined with a breast lesion in 29 pa-
tients), mean CA 15.3 level was 153 IU/ml 
(range: 0–2240: SD: 303 IU/ml). Mean CA 
15.3 levels in patients presenting with 
metastatic disease on FDG PET-CT im-
aging proved significantly different from 
that obtained in patients with normal scan 
findings and patients presenting with 
locoregional disease (p ≤ 0.008). Inversely, 
mean CA 15.3 levels in patients presenting 
with normal scan findings or presenting 
with loco-regional disease proved not sig-
Fig. 1 ROC-curve analysis revealed an AUC of 0.695 with 95%CI: [0.642–0.740] for CA 15.3 to separ-
ate FDG PET-CT positive from FDG PET-CT negative findings.
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nificantly different (p = 0.584). The area 
under the CA 15.3 ROC-curve for separat-
ing normal scan findings from metastatic 
disease was 0.732 (p = 0.0001). Using a cut-
off value of 34.2 IU/ml a sensitivity of 69% 
and specificity of 69% was obtained. The 
area under the CA 15.3 ROC-curve for 
separating normal scan findings from 
locoregional disease was 0.527 (p = 0.587) 
(▶ Fig. 2a, ▶ Fig. 2b). 
Receptor status
CA 15.3 levels measured in estrogen-recep-
tor positive breast carcinoma proved not 
significantly different from those obtained 
in estrogen receptor negative breast carci-
noma ((n=82)  : 73 IU/ml (range: 0–1100 
IU/ml) versus (n=258) : 81 IU/ml 
(range: 0–2240 IU/ml) (p = 0.603)). AUC’s 
under the curve for CA 15.3 to separate 
positive from negative FDG PET-CT scan 
findings, in ER-receptor positive and ER-
receptor negative patients were respectively 
0.772 ( p = 0.0001) and 0.596 (p = 0.143). 
The AUC in ER-negative patients proved 
significantly smaller when compared to 
that obtained in ER-positive patients (p = 
0.01) (▶ Fig. 3). 
CA 15.3 levels measured in PR-positive 
breast carcinoma proved significantly 
higher compared to those obtained in PR-
negative breast carcinoma ((n=192) : 93 
IU/ml (range: 0–1100 IU/ml) versus 
(n=106) : 53 IU/ml (range: 8–708 IU/ml) 
(p = 0.006)) (▶ Fig. 4a). AUCs under the 
curve for CA 15.3 to separate positive from 
negative FDG PET-CT scan findings, in 
PR-positive and PR-negative patients were 
Fig. 2 The area under the CA 15.3 ROC-curve for separating normal scan findings from  
a) locoregional disease: 0.527 (p = 0.587); b) metastatic disease: 0.732 (p = 0.0001)
a b
Fig. 3 Measurements of CA 15.3 to separate positive from negative FDG PET-CT scan findings were 
more pronounced in ER receptor positive than ER-receptor negative patients. This result is in accordance 
with the ROC-curve analysis (# 1 ERposPETpos; # 2 ERposPETneg; # 3 ERnegPETpos; # 4 ERnegPETneg).
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Figure 3 ‘CA 15.3 related to subgroups’
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respectively 0.675 (p = 0.0001) and 0.694 (p 
= 0.0001) (▶ Fig. 4b, ▶ Fig. 4c). 
CA 15.3 levels measured in HER2-posi-
tive breast carcinoma proved not signifi-
cantly different from those obtained in 
HER2-negative breast carcinoma ((n= 304) 
 : 108 IU/ml (range: 0–2240 IU, /ml) ver-
sus (n=75) : 86 IU/ml (range: 12–708 
IU/ml) (p=0.465)). AUC’s under the curve 
for CA 15.3 to separate positive from 
negative FDG PET-CT scan findings, in 
HER2-positive and negative patients were 
respectively 0.594 (p = 0.178) and 0.701 (p 
= 0.0001) (▶ Fig. 5). The AUC in 
HER2-negative patients proved signifi-
cantly higher compared to that obtained in 
HER2positive patients (p = 0.01). 
Blood volume corrected CA 15.3 
measurements
Mean blood volume was 4.0 l (range: 
2.6–6.0 l; SD: 0.6 l). Blood-volume cor-
Fig. 4 a) CA 15.3 levels measured in PR-positive breast carcinoma proved significantly higher compared to those obtained in PR-negative breast carcinoma. 
b, c) AUCs under the curve for CA 15.3 to separate positive from negative FDG PET-CT scan findings, in PR-positive and PR-negative patients were0.675 (p = 
0.0001) and 0.694 (p = 0.0001), respectively.
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Figure 4a ‘CA 15.3 related to PR-status’
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local and systemic disease and 92 out of 
115 patients with metastatic disease had in-
creased CA 15.3 levels. The levels of CA 
15.3 in the latter group did not differ be-
tween single or multiple sites nor between 
the sites of metastasis (lung, liver and bone) 
(3). On the other hand, in a series by Co-
lomer et al. in 173 patients with advanced 
breast carcinoma, elevated CA 15.3 values 
(greater than 40 IU/ml) were seen in 130 
patients and values obtained correlated 
well with the estimated extent of metastatic 
disease and number of metastases (22).
While in the series presented, CA 15.3 
levels proved not significantly different be-
tween estrogen-receptor positive and es-
trogen-receptor negative patients, the AUC 
value for CA 15.3 to separate positive from 
negative FDG PET-CT findings in es-
trogen-receptor positive patients proved 
significantly higher when compared to that 
obtained in estrogen- receptor negative pa-
tients (0.772 versus 0.596; p = 0.01). In the 
breast cancer cell lines MCF-7 and T47D, 
MUC-1/SEC was shown to be dependent 
on estrogen expression; the estrogen recep-
tor alpha could bind estrogen response el-
ements (EREs) that are present in the 
MUC-1 promotor. In turn, MUC-1 was 
shown to activate and stabilize ER-á by 
binding to the DNA-binding domain of the 
receptor enhancing its activation. Fur-
thermore, MUC1 was shown to promote 
estradiol mediated growth and survival of 
breast cancer cells (4). In line with these 
preclinical findings, Park et al. showed in a 
series of 707 patients who were diagnosed 
with metastatic or recurrent breast cancer 
that supranormal levels of CA 15.3 are 
more frequently observed in hormone re-
ceptor positive patients, estrogen receptor 
positive and/or progesterone receptor posi-
tive (16). Bensouda et al. reported similar 
findings in a series of 272 patients in whom 
CA 15.3 was increased in 168 patients at 
diagnosis of metastases and found to be 
elevated in 69% of hormone receptor posi-
tive patients versus 46 % of hormone re-
ceptor negative patients (2). The close bio-
logical link between the secretion and 
serum levels of MUC-1, from which the 
CA 15.3 epitope is derived, and estrogen 
receptor status as suggested by these 
studies is in line with the higher AUC 
found in estrogen receptor positive patients 
including 1050 normal control subjects, 
9.4% of normal controls had CA 15.3 levels 
greater than 22 U/ml while that from 5.5% 
and 1.3% had levels greater than 25 U/ml 
and 30 U/ml. Inversely, only 13 of 26 pa-
tients presenting with loco-regional disease 
had CA 15.3 levels greater than 22 U/ml 
(13). Finally, in a series by Stieber et al. in-
cluding 272 apparently healthy individuals, 
34 pregnant women, 308 benign diseases, 
273 cancers other than breast cancer and 
439 breast cancer patients, 12% of patients 
presenting with benign breast disease had 
CA 15.3 levels ≥ 25 IU/ml (21). On the 
other hand, small clusters of tumoral cells 
may be missed by FDG PET imaging due 
to the relatively poor spatial resolution of 
this imaging modality, around 5–6 mm, 
and related partial volume effects (11). In-
versely, in patients presenting with meta-
static disease (with or without associated 
loco-regional involvement) on FDG PET-
CT imaging, CA 15.3 values proved signifi-
cantly higher when compared to patients 
with normal scan findings or presenting 
with locoregional disease; using a cut-off 
value of 34.2 IU/ml for CA 15.3, a sensitiv-
ity and specificity for separating normal 
scan findings from positive scan findings of 
both 69% were obtained. Again, this find-
ing is in line with previous data, respect-
ively reported by Gerachty et al. and Colo-
mor et al. (6, 9). In the study by Gerachty et 
al. 22 out of 23 patients with combined 
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rected, global CA 15.3 levels varied from 
0–12765 IU (mean: 463 IU (SD: 1186 IU). 
ROC-curve analysis revealed an AUC of 
0.670 (p = 0.0001) for blood-volume cor-
rected total CA 15.3 to separate FDG PET-
CT positive from FDG PET-CT negative 
findings, similar to the AUC value for CA 
15.3 blood volume uncorrected measure-
ments (see whole group) (▶ Fig. 6a, 
▶ Fig. 6b). 
Discussion
In the series presented, mean CA 15.3 lev-
els in patients presenting with normal scan 
findings or presenting with loco-regional 
disease proved not significantly different 
from each other. The area under the CA 
15.3 ROC-curve for separating normal 
scan findings from locoregional disease 
was 0.527 (p = 0.587) suggesting CA 15.3 is 
neither a sensitive nor specific biomarker 
for predicting loco-regional recurrence. 
Previous studies have already shown that 
serum CA 15.3 levels in patients with loca-
lised breast cancer largely overlap those 
found in healthy women or women with 
benign breast disease (15). Geraghty et al. 
studied 129 patients presenting with recur-
rent breast carcinoma. Out of 14 patients 
with isolated loco-regional disease, only 
one patient had increased levels of CA 15.3 
(> 25 IU/ml) (9). In a series by Hayes et al. 
Fig. 5 
AUCs under the curve 
for CA 15.3 to separ-
ate positive from 
negative FDG PET-CT 
scan findings in HER2 
negative patients was 
0.701 (p = 0.0001).
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Fig. 6 Ca15.3 measurements (a) and Ca 15.3 corrected for blood volume (b) were significantly higher 
in patients with a positive PET-scan compared to those obtained in patients with a negative PET-scan.
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when compared to estrogen receptor 
negative patients is not surprising. While 
expression of the progesterone receptor ex-
pression also requires a functional estrogen 
receptor, similar to MUC-1, in this series, 
it’s absence or presence did not signifi-
cantly impact the AUC for CA 15.3 sug-
gesting different pathways may be involved 
regulating their transcription. Of interest, 
the AUC in HER2-negative patients proved 
significantly higher when compared to that 
obtained in HER2-positive patients (0.701 
versus 0.594 (p = 0.01). The inverse rela-
tionship between HER2 over-expression 
and estrogen or progesterone receptor ex-
pression is well known (1, 14, 19). While 
ER and PR are not an independent predic-
tor for the HER2-status in young women, 
they are in patients older than 45 years of 
age (4). In the series presented, the mean 
age of the patients at the time of diagnosis 
was 51.4 years, thus the good AUC found 
in HER2-negative patients in our series is 
most likely a reflection of the predominant 
ER-positive status of these patients.
Finally, for similar sized breast lesions 
producing similar amounts of CA 15.3 in 
different patients, different CA 15.3 
measurements may be obtained due to dif-
ferences in circulating blood volume; 
smaller blood volumes are likely to yield 
higher CA 15.3 measurements.
Limitations 
When performing ROC analysis, ideally 
one imaging episode/patient should be in-
cluded in order to avoid too high an impact 
of a single individual on the area-under the 
curve. In the series presented, we included 
several PET-CT imaging data sets per pa-
tient. However, as this was the case for all 
patients included (on average 5 PET-CT 
examinations per patient) and imaging 
data sets were acquired over a large period 
of time, reflecting various clinical situ-
ations in one patient, it is unlikely that cu-
toff values defined in the series presented 
are impacted significantly by single indi-
viduals included in the study. Furthermore, 
cut-off values identified are similar to those 
previously reported in the literature.
Conclusion
In this series, the AUC for CA 15.3 
measurements to separate FDG PET/CT 
positive from negative findings in breast 
cancer patients in whom a recurrence was 
suspected proved to be directly related to 
the extent of the recurrent disease (loco-re-
gional versus metastatic disease) and hor-
mone receptor status (ER + versus ER –) 
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and inversely related to HER2 status. The 
wide variability reported in literature in 
terms of sensitivity and specificity for iden-
tifying breast cancer recurrence using vari-
ous cut-offs of CA 15.3 to guide FDG PET/
CT imaging may thus in part be explained 
by differences in proportions of such pa-
tients being included. Correcting CA15.3 
measurements for blood volumes did not 
impact the AUC. 
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